Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Want to see LRMR full AI Analyst Report?
Top Page
Larimar Therapeutics
(NASDAQ:LRMR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.50
▼(-27.08% Downside)
Action:Reiterated
Date:05/20/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and accelerating cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting these risks are constructive corporate catalysts, including Breakthrough Therapy Designation and stated progress toward a 2026 BLA/Phase 3 program, but financing/dilution risk remains material.
Positive Factors
Regulatory Progress / Breakthrough
Breakthrough Therapy designation and FDA alignment on a surrogate (skin frataxin) and key endpoints materially improve the regulatory path. This durable regulatory backing raises the probability of accelerated review and a viable approval pathway, shortening time-to-market and supporting strategic partnerships.
Negative Factors
Pre-revenue / Large Losses
As a development-stage biotech with no product revenue, the company records substantial recurring losses (~$166M TTM). This persistent unprofitability limits internal funding options, increases dependence on external capital, and raises execution risk if clinical or regulatory setbacks occur.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress / Breakthrough
Breakthrough Therapy designation and FDA alignment on a surrogate (skin frataxin) and key endpoints materially improve the regulatory path. This durable regulatory backing raises the probability of accelerated review and a viable approval pathway, shortening time-to-market and supporting strategic partnerships.
Read all positive factors
Larimar Therapeutics (LRMR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$366.71M
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue GrowthN/A
EPS Growth-39.31%
CountryUS
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.10
Shares Outstanding103,882,935
10 Day Avg. Volume2,050,682
30 Day Avg. Volume1,599,547
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.47K
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$16.00Price Target Upside233.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.97
Revenue Forecast (FY)N/A
Larimar Therapeutics Business Overview & Revenue Model
Company Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinic...
How the Company Makes Money
Larimar Therapeutics is a clinical-stage company and, as such, it generally does not generate recurring revenue from commercial product sales because it does not have an approved product on the market. Its ability to fund operations is therefore t...
Larimar Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -87.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -170.38M | -172.15M | -90.57M | -41.45M | -36.21M | -50.14M |
| Net Income | -166.00M | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
Balance Sheet | ||||||
| Total Assets | 208.51M | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M |
| Cash, Cash Equivalents and Short-Term Investments | 200.38M | 136.85M | 183.45M | 86.79M | 118.43M | 70.10M |
| Total Debt | 3.78M | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M |
| Total Liabilities | 50.48M | 67.76M | 28.41M | 14.21M | 15.50M | 14.25M |
| Stockholders Equity | 158.03M | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M |
Cash Flow | ||||||
| Free Cash Flow | -131.32M | -113.29M | -71.28M | -33.62M | -27.67M | -42.44M |
| Operating Cash Flow | -131.28M | -113.20M | -70.76M | -33.46M | -27.57M | -42.10M |
| Investing Cash Flow | 114.86M | 100.31M | -85.39M | 33.35M | -90.96M | 24.17M |
| Financing Cash Flow | 173.20M | 65.09M | 161.88M | 30.00K | 75.26M | 19.89M |
Larimar Therapeutics Technical Analysis
Negative
4.80
Price Trends
4.44
Negative
4.13
Negative
4.02
Negative
Market Momentum
-0.28
Positive
35.93
Neutral
15.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LRMR, the sentiment is Negative. The current price of 4.8 is above the 20-day moving average (MA) of 4.02, above the 50-day MA of 4.44, and above the 200-day MA of 4.02, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 35.93 is Neutral, neither overbought nor oversold. The STOCH value of 15.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LRMR.
Larimar Therapeutics Risk Analysis
Larimar Therapeutics disclosed 84 risk factors in its most recent earnings report. Larimar Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Larimar Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $896.01M | 3.39 | -54.39% | ― | ― | ― | |
55 Neutral | $564.91M | -8.62 | -60.42% | ― | ― | 26.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $371.64M | -2.11 | -61.41% | ― | 8.16% | -434.76% | |
49 Neutral | $318.69M | -1.64 | -181.70% | ― | ― | 17.61% | |
47 Neutral | $366.71M | -3.24 | -134.14% | ― | ― | -39.31% | |
46 Neutral | $234.86M | -4.18 | 85.78% | ― | 20.08% | 14.06% |
* Healthcare Sector Average
LRMR
Larimar Therapeutics
3.53
1.60
82.90%
OMER
Omeros
12.38
9.27
298.07%
VNDA
Vanda
6.18
1.86
43.06%
FHTX
Foghorn Therapeutics
4.00
-0.06
-1.48%
CADL
Candel Therapeutics
7.71
2.24
40.95%
NMRA
Neumora Therapeutics, Inc.
1.72
0.97
129.33%
Larimar Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Larimar Shareholders Approve Governance and Capital Structure Changes
Positive
May 19, 2026
On May 19, 2026, Larimar Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually, where shareholders elected Class III directors Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt to serve until the 2029 annual meeting a...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress
Positive
May 14, 2026
On May 14, 2026, Larimar Therapeutics reported first-quarter 2026 results and detailed regulatory and clinical progress for nomlabofusp in Friedreich’s ataxia. The company highlighted its intention to begin a rolling biologics license applic...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Larimar Advances Nomlabofusp Toward 2026 BLA Submission
Positive
Mar 9, 2026
On March 9, 2026, Larimar Therapeutics posted an updated corporate presentation outlining progress in its nomlabofusp program for Friedreich’s ataxia and ongoing regulatory engagement. The company reported that the FDA has granted nomlabofus...
Private Placements and Financing
Larimar Therapeutics Announces Upsized Public Equity Offering
Positive
Feb 27, 2026
On February 25, 2026, Larimar Therapeutics, Inc. entered into an underwriting agreement with a syndicate led by J.P. Morgan Securities LLC and Guggenheim Securities, LLC for a public offering of 20,000,000 shares of its common stock at $5.00 per s...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
FDA Grants Breakthrough Therapy Status to Larimar’s Nomlabofusp
Positive
Feb 24, 2026
On February 24, 2026, Larimar Therapeutics said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its lead candidate nomlabofusp for treating adults and children with Friedreich’s ataxia, reflecting preliminar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.